Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

NCT05900388 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05900388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05900388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism
Lead sponsor
Bayer
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2027
Completion date
June 30, 2029
Enrollment
850 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

children under 2 years, venous thromboembolism